Anika Therapeutics (ANIK) Change in Accured Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has reported Change in Accured Expenses for 17 consecutive years, with $265000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 112.25% year-over-year to $265000.0 in Q2 2026; TTM through Jun 2026 was $2.7 million, a 167.16% increase from a year earlier, with the FY2025 full-year figure at -$1.5 million, up 59.12% from the prior year.
• Change in Accured Expenses was $265000.0 for Q2 2026 at Anika Therapeutics, up from -$1.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.6 million in Q3 2023 and troughed at -$4.3 million in Q2 2023.
• A 5-year average of -$279888.9 and a median of -$208500.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 255.3% in 2023 and plunged 567.67% in 2024, its largest moves.
• Over 5 years, Change in Accured Expenses stood at -$558000.0 in 2022, then surged by 231.54% to $734000.0 in 2023, then tumbled by 227.38% to -$935000.0 in 2024, then soared by 115.08% to $141000.0 in 2025, then jumped by 87.94% to $265000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $265000.0 (Q2 2026), -$1.3 million (Q1 2026), and $141000.0 (Q4 2025), per Business Quant data.